Allergan oral migraine drug succeeds in study

Allergan Plc said its oral migraine drug met the main goal across all doses in a study, with a statistically significant reduction in monthly headache days in patients with episodic migraine.

The treatment, atogepant, belongs to a class of migraine drugs also being developed by Eli Lilly and Alder Biopharmaceuticals that target a protein associated with pain signaling called calcitonin gene-related peptide (CGRP).

Last month, the U.S. Food and Drug Administration approved Amgen Inc’s CGRP treatment Aimovig, which is self-injected monthly and will have a list price of $6,900 a year, or $575 a month.

Last month, the company reported positive results from a second late-stage trial for the 50-milligram dose of its other migraine drug ubrogepant.